You do not have permission to access this chart.
Please Sign Up or Login

About:

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

Employees:

130

Address:

Alimera Sciences, Inc. 6120 Windward Parkway Suite 290 Alpharetta GA 30005 United States

Website:

HOME

Phone:

678-990-5740

Leave a comment

Your email address will not be published. Required fields are marked *